Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Solid Tumours 3Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Papillary renal cell carcinoma, sporadic 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Cisplatin 258Radiotherapy 193Cetuximab 151pembrolizumab 123Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 78Radiotherapy, Intensity-Modulated 72Surveys and Questionnaires 46Nivolumab 42Drug Therapy 34Radiation 33Blood Specimen Collection 27Erlotinib Hydrochloride 26Gemcitabine 25Immunohistochemistry 22Gefitinib 22Cyclophosphamide 22Surgical Procedures, Operative 21Standard of Care 20durvalumab 19Pemetrexed 19Magnetic Resonance Spectroscopy 19Radiosurgery 17Capecitabine 17Chemotherapy, Adjuvant 16Celecoxib 16Biopsy 16atezolizumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × GSK 1363089 × Clear all
NCT00725764 2017-10-16

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

GlaxoSmithKline

Phase 2 Completed
14 enrolled 14 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡